Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that ritlecitinib was generally well tolerated over 72 months in patients aged 12 and older with alopecia areata, with adverse events like headache and nasopharyngitis observed, and safety outcomes consistent with previous studies.

In a non-blinded study with 12 Japanese participants, applying a lotion containing Lactiplantibacillus plantarum N793 to the scalp for 24 weeks significantly increased hair density and reduced hair loss, with participants reporting improvements in hair thickness and volume, and the treatment deemed safe.

In this case study, a 69-year-old woman with pityriasis rubra pilaris developed a scarring alopecia with lichen-planopilaris-like features, which responded well to early treatment.

In this study, methotrexate therapy with or without corticosteroids showed similar efficacy and safety in treating patients with lichen planopilaris, with no significant differences in the primary outcome or adverse effects between the two groups.

This review discusses the biological properties and potential applications of PCL and barium titanate composites in biomedical fields and reports no new experimental findings; the authors highlight the need for further research.

In this case study, a woman with frontal fibrosing alopecia and associated hyperpigmentation showed significant improvement in skin pigmentation and itch after 9 months of treatment with mycophenolate mofetil, highlighting its therapeutic potential for lichen planus pigmentosus linked to this condition.

This study found that oral retinoid therapy may provide clinical improvement in a small percentage of patients with treatment-resistant lichen planopilaris, although it is not commonly used as a first-line treatment.

This study reviewed cases of Graham–Little-Piccardi–Lassueur syndrome and found that topical treatments were generally ineffective, while systemic therapies like prednisone, hydroxychloroquine, and isotretinoin led to partial hair regrowth and disease stabilization, highlighting the importance of early diagnosis and systemic therapy to improve outcomes.

This review discusses the use of Tisseel for stabilizing particulate grafts and reports no new clinical results; the authors emphasize the need for further controlled trials.

This study found that a new lecithinized coal tar formulation did not stain different types of mammalian hair, suggesting it may be promising for treating scalp psoriasis without the drawback of staining.

This report describes a unique case of linear lichen planus pigmentosus on the face with histological features of lichen planopilaris, which has not been documented before.

In this report, NICE has approved ritlecitinib, an oral kinase inhibitor, as the first recommended treatment for severe alopecia areata in individuals aged 12 and older.

This case report describes a patient with lichen planopilaris who experienced remarkable hair regrowth at a previously scarred area after treatment with low-dose naltrexone and platelet-rich plasma, following minimal response to other therapies.

It's important to tell the difference between hair casts, pseudocasts, and nits.

In this study, two cases of idiopathic hair casts in young girls responded well to 0.025% tretinoin lotion, with analyses suggesting an infrainfundibular origin for the lesions.

In this study, researchers reported that treating alopecia areata patients with ritlecitinib led to progressive improvements in emotional symptoms and activity limitations over 48 weeks, though the post hoc analysis and trial setting suggest caution in interpreting the findings for broader populations.

This study found that integrating Lactobacillus-rich probiotic nutrition and fractional CO₂ laser therapy with clotrimazole in mucoadhesive hydrogels significantly improved clinical and structural outcomes for women with recurrent vulvovaginal candidiasis, suggesting a promising advanced therapy, though further validation in larger trials is needed.

This chapter provides dermatology trainees with insights on managing lichen planopilaris, emphasizing treating active disease to prevent further hair loss and recommending a tapered course of oral steroids for disease stabilization.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

This study explored the potential of the lysate and lipoteichoic acid from Lactiplantibacillus plantarum APsulloc 331261 to improve scalp seborrheic dermatitis by modulating inflammatory and lipogenesis pathways in vitro, suggesting potential as a natural treatment option.

This review examines the dermatologic side effects of lithium, noting it can cause or worsen skin conditions like psoriasis and acne, potentially affecting medication adherence, but reports no new clinical results.

Hair relaxers are linked to reduced cystine levels and potential hair damage.

This case series reported that low-dose naltrexone may benefit patients with lichen planopilaris by reducing scalp symptoms and slowing disease progression, with no adverse effects observed in the patients.

In this study, a case of lichen amyloidosis on the scalp significantly improved with a 2-month topical treatment using clobetasol propionate/all-trans retinoic acid ointment.

This article discusses the use of Espumil foam base in pharmacies for preparing dermatological medications and reports no new clinical results.

In this case study, a patient with refractory oral lichen planus experienced marked improvement within one month of daily treatment with baricitinib, contributing to the evidence supporting the use of JAK inhibitors for lichen planus.

This article reviews the pathogenesis, complications, and management of lichen planus, especially its persistent oral form, and highlights the need for further prospective studies.